| Host: |
Goat |
| Applications: |
Pep-ELISA/WB/IHC |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Goat polyclonal antibody anti-MTA1 (Internal) is suitable for use in ELISA, Western Blot and Immunohistochemistry research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
| Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Concentration: |
0.5 mg/mL |
| Dilution Range: |
WB-0.03-0.1µg/mlIHC-3.75µg/mlELISA-antibody detection limit dilution 1:16000. |
| Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
| Gene Symbol: |
MTA1 |
| Gene ID: |
9112 |
| Uniprot ID: |
MTA1_HUMAN |
| Immunogen Region: |
Internal |
| Accession Number: |
AAA78935.1 |
| Specificity: |
Immunizing peptide was designed based on NP_004680.1. The version changed to NP_004680.2 and no longer matches with the peptide. |
| Immunogen Sequence: |
PGDVFYMPKE |
| Post Translational Modifications | Phosphorylation by CSNK1G2/CK1 triggered by estrogen enhances corepression of estrogen receptor (ER). Acetylation is essential for its transcriptional coactivator activity. Sumoylation positively regulates its transcriptional corepressor activity but does not affect the protein stability. Sumoylated preferentially by SUMO2 or SUMO3 than SUMO1. Sumoylation is enhanced by PIAS1/3/4 and preferentially sumoylated by SUMO2 in the presence of PIAS1/3/4. Desumoylated by SENP1. Ubiquitinated by COP1, which leads to proteasomal degradation. |
| Function | Transcriptional coregulator which can act as both a transcriptional corepressor and coactivator. Acts as a component of the histone deacetylase NuRD complex which participates in the remodeling of chromatin. In the NuRD complex, regulates transcription of its targets by modifying the acetylation status of the target chromatin and cofactor accessibility to the target DNA. In conjunction with other components of NuRD, acts as a transcriptional corepressor of BRCA1, ESR1, TFF1 and CDKN1A. Acts as a transcriptional coactivator of BCAS3, and SUMO2, independent of the NuRD complex. Stimulates the expression of WNT1 by inhibiting the expression of its transcriptional corepressor SIX3. Regulates p53-dependent and -independent DNA repair processes following genotoxic stress. Regulates the stability and function of p53/TP53 by inhibiting its ubiquitination by COP1 and MDM2 thereby regulating the p53-dependent DNA repair. Plays a role in the regulation of the circadian clock and is essential for the generation and maintenance of circadian rhythms under constant light and for normal entrainment of behavior to light-dark (LD) cycles. Positively regulates the CLOCK-BMAL1 heterodimer mediated transcriptional activation of its own transcription and the transcription of CRY1. Regulates deacetylation of BMAL1 by regulating SIRT1 expression, resulting in derepressing CRY1-mediated transcription repression. With TFCP2L1, promotes establishment and maintenance of pluripotency in embryonic stem cells (ESCs) and inhibits endoderm differentiation. Isoform Short: Binds to ESR1 and sequesters it in the cytoplasm and enhances its non-genomic responses. |
| Protein Name | Metastasis-Associated Protein Mta1 |
| Database Links | Reactome: R-HSA-3214815Reactome: R-HSA-3232118Reactome: R-HSA-427389Reactome: R-HSA-73762Reactome: R-HSA-8943724Reactome: R-HSA-9679191 |
| Cellular Localisation | NucleusIsoform Short: CytoplasmIsoform Long: NucleusNucleus EnvelopeCytoplasmCytoskeletonAssociated With MicrotubulesLocalization At The Nuclear Envelope Is Tpr-Dependent |
| Alternative Antibody Names | Anti-Metastasis-Associated Protein Mta1 antibodyAnti-MTA1 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
